Glaucoma

Results of the evaluation of two-year post-surgical safety and efficacy of canaloplasty to treat open angle glaucoma (OAG) have been published in the Journal of Cataract and Refractive Surgery. Dr Richard A Lewis et al., concluded that the procedure was safe and effective in reducing IOP in adult OAG patients.

Novagali Pharma, the French pharmaceutical ophthalmic company, is to conduct a Phase III clinical trial of Catioprost (Nova21027) its Investigational New Drug Application (IND).

A look at how to introduce canaloplasty into your surgery; experience from two doctors.

New guidelines, designed to improve the management and diagnosis of chronic open angle glaucoma (COAG) and ocular hypertension have received a cautious commendation from the ophthalmic community.

A worldwide licensing agreement for tafluprost, preserved and preservative-free formulations, has been announced between Merck & Co Inc., and Santen Pharmaceutical Co Ltd.

A Swiss startup company, Sensimed, has developed a novel technology for measuring increases in intraocular pressure.

The investigative research group Catalyst for a Cure has made significant discoveries developing a better understanding of the insidious changes caused by glaucoma and is developing strategies to prevent them.

Dr Christoph Kranemann examines the medium-term success and complication rate of mitomycin-assisted bleb needlings.

While researching the long-suspected gene linked to glaucoma, WDR36, Michael Walter, PhD, and team discovered that the gene STL1 is only one of many other genes in which mutations must take place in order for WDR36 to cause glaucoma.

Dr Vikas Shankar has found that in the diabetic population with OAG, the optic nerve damage occurs at a lower intraocular pressure in comparison with the non-diabetic OAG population and asks: does screening hold the key?

Quantitative analysis of colour vision defects provides the possibility of follow-up and may be a useful means for detecting early glaucomatous changes in patients with normal visual fields.

The investigative research group Catalyst for a Cure has made significant discoveries developing a better understanding of the insidious changes caused by glaucoma and is developing strategies to prevent them.

iForum, a surgeon-support website to enable the adoption of canaloplasty into clinicians' practices, has been launched by iScience Interventional.

The eyecare nutritional supplement market is worth $43.4 million and is projected to grow to $87.4 million within five years, according to research by Frost & Sullivan.

The first data on Nova21027 (Novagali Pharma), a benzalkonimum chloride (BAK)-free latanoprost cationic emulsion, have been announced at the Scientific Meeting of the Association for Ocular Pharmacology and Therapeutics (AOPT) in Salzburg, Austria.

Public screenings will take place at a variety of venues including private practices and hospitals in Austria, Belgium, Bulgaria, Greece, Italy, Spain and Switzerland.

The Motion Displacement Test (MDT), developed by Moorfields Eye Hospital in partnership with UCL Institute of Ophthalmology and City University London will be on show during World Glaucoma Day (March 12th) to demonstrate some of the latest glaucoma diagnostic equipment.

Dr Tiziana Fattori of Per Vedere Fatti Vedere onlus in Italy explains the reasons behind the launch of a campaign to abolish bureaucratic procedures inhibiting patients from undertaking treatment for glaucoma.

David Garway-Heath examines HRT output as a component in the early glaucoma detection arsenal.

Christopher Girkin discusses how FDT technology predicts disease developments better than SAP.

Neil Choplin considers the importance of retinal nerve fibre loss in early glaucoma.

The Diaton tonometer (BiCOM), a non-invasive and painless way to measure intraocular pressure (IOP) through the eyelid, has been showcased by Phycon Medical at the 2009 meeting of the Florida Osteopathic Medical Association (FOMA).

Dynamic contour tonometry (DCT) may be more accurate than Goldmann applanation tonometry (GAT) in measuring intraocular pressure (IOP), according to study results published in the February issue of Eye.

OPKO Health, Inc has received FDA marketing clearance on an imaging device and launched clinical trials of a new glaucoma shunt, the company has announced.

The National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3RS) has awarded its annual prize to a project exploring the use of stem cells for treating glaucoma and other eye diseases.

A laser-based surgical device has been shown during trials to provide a safe, non-penetrating method of reducing intraocular pressure (IOP), according to study results published by the developer of the device, IOPtima Ltd.

The TrueField Analyser, a glaucoma testing device, has been hailed by reseachers at the Australian National University as offering faster, more comprehensive and more accurate diagnoses than current methods.

CORM-3, a water-soluble carbon monoxide-releasing molecule, is associated with a intraocular pressure (IOP) lowering in animal models of ocular hypertension, concluded a study published in the January issue of the British Journal of Ophthalmology.

Deep sclerectomy with MMC is safer and more effective than trabeculectomy or tube surgery, according to Dr Nitin Anand.

Trabeculectomy with MMC and Ex-PRESS shunt device placement appears to be safer than other treatment methods, according to Dr Leon Herndon.